IDEAYA Partners with Genentech to Test Pancreatic Cancer Drug Combo
Event summary
- IDEAYA Biosciences and Genentech will co-develop IDE892 (PRMT5 inhibitor) with RG6620 (KRAS G12D inhibitor) for MTAP-deleted pancreatic cancer.
- Genentech will sponsor the clinical trial, with joint governance overseeing the study.
- MTAP deletions and KRAS G12D mutations co-occur in ~15% of pancreatic ductal adenocarcinoma (PDAC) patients.
- IDE892 is described as a potential best-in-class MTA-cooperative PRMT5 inhibitor with favorable drug-like properties.
- IDEAYA plans to initiate another Phase 1 combination cohort with Roche's RG6505 in MTAP-deleted, RAS-mutant PDAC in 2H 2026.
The big picture
This collaboration underscores the growing focus on targeted therapies for genetically defined subsets of pancreatic cancer, a field with high unmet medical need. IDEAYA's strategy of combining its PRMT5 inhibitor with KRAS-directed therapies aligns with broader industry trends toward synthetic lethality and precision oncology. The deal also highlights Roche's commitment to expanding its KRAS inhibitor pipeline through strategic partnerships.
What we're watching
- Combination Efficacy
- Whether IDE892 and RG6620 can drive deeper, more durable responses in MTAP-deleted KRAS G12D-mutant pancreatic cancer.
- Clinical Timeline
- The pace at which IDEAYA and Genentech advance the Phase 1 combination cohort with RG6505 in 2H 2026.
- Competitive Positioning
- How IDEAYA's MTAP-deletion portfolio compares to other precision oncology approaches in pancreatic cancer.
Related topics